Hybrid Bayesian And Frequentist Clinical Trial Designs
By Yannis Jemiai, Natalia Muhlemann , Rajat Mukherjee , Pantelis Vlachos , Apurva Bhingare , Yuan Ji
Most people know that clinical drug discovery is usually conducted using either Frequentist or Bayesian methods. These two statistical paradigms have enjoyed a degree of competition historically, with some statisticians tauting the statistical rigor of Frequentist designs and others the intuitiveness and flexibility of Bayesian clinical trials. Recently, though, a number of hybrid methods have arisen, that leverage the benefits of both paradigms for singularly powerful clinical trials. There are benefits of these combined methods.
Signing up provides unlimited access to: